blog background

FDA launches new medical device tracking site

July 28, 2015
Copied to clipboard
AccessGUDID will allow public access to key safety information for medical devices.

On Monday, May 4, the FDA announced the launch of AccessGUDID, its latest effort towards improving insight into the performance of medical devices on the market.  The site contains a vast trove of information on devices sold within the U.S., from the pre-trial stage to distribution figures. 

The site was a joint effort between the FDA, the National Institutes of Health (NIH) and the National Library of Medicine (NLM). It is currently open to the public, meaning anyone curious about a device, such as whether a certain model was subject to a recall, will have quick and easy access to the information they seek. 

“Through AccessGUDID, anyone can search or download information that labelers have submitted about their medical devices to the GUDID,” FDA explained in a press statement. “Device identification and key safety information, such as whether the device is safe for use while undergoing MRI, will be available for health care providers to search at any time.”

The initiative was originally begun in 2013, when the FDA first finalized its Unique Device Identification Rule after requests from both the industry and public officials for improved visibility into long-term device efficacy. This latest effort should continue to help improve the industry’s ability to react to adverse event reports and identify and track problems that could be associated with a particular device. The FDA estimated that about 50,000 serious adverse events related to medical devices are reported each year.

Moving forward, most medical devices will now be required to have a UDI on their label and packaging, and in select cases, etched on the device itself. UDIs for existing devices will be released over the following few years, with the highest-risk devices being assigned first. 

Latest Industry News

Moximed MISHA Knee System for osteoarthritis demonstrates superiority over HTO
MMI is proud to have partnered with Moximed on an FDA-regulated IDE study to investigate the safety and effectiveness of the MISHA Knee System as a treatment option for younger patients with mild to moderate OA.
DiscGenics Announces FDA RMAT Designation
The FDA granted RMAT designation to DiscGenics’ Injectable Disc Cell Therapy for degenerative disc disease.
FDA no longer requires animal tests before human drug trials
A newly signed law permits the FDA to clear a drug for human clinical trials while bypassing animal trials.